|
|
Post by brotherm1 on Dec 16, 2017 12:44:08 GMT -5
|
|
|
|
Post by sportsrancho on Dec 23, 2017 10:00:20 GMT -5
Browse Open Jobs
Showing Records: 1 - 10
Total Records: 13
Post Date Requisition Number Title City State
11/16/2017 17-0059 Manager - Financial Planning & Analysis Westlake Village CA
5/24/2017 17-0016 Facilities Specialist Danbury CT
11/1/2017 17-0055 Area Business Manager New Orleans LA
8/10/2017 17-0044 Sales Analyst, Sales Operations Westlake Village CA
12/23/2017 17-0061 Regional Business Manager (Texas) Dallas TX
12/23/2017 17-0062 Regional Business Manager (Northern Tier - Pittsburgh, Cleveland, Buffalo) Pittsburgh, Cleveland, or Buffalo
12/23/2017 17-0063 Area Business Manager (Houston-Liberty, TX) Houston TX
12/23/2017 17-0064 Area Business Manager (Rio Grande Valley, TX) Rio Grande Valley TX
12/23/2017 17-0065 Area Business Manager (Santa Barbara, CA) Santa Barbara CA
12/23/2017 17-0066 Area Business Manager (Fresno, CA) Fresno CA
|
|
|
|
Post by sportsrancho on Dec 26, 2017 17:05:41 GMT -5
@tinkering2 @biobull @biolordvr I called MNKD Danbury & asked to speak to CMO, was told they just hired him & gave me name Michael Friedman
@kevinmik @biobull @biolordvr And looks like this Michael is still on Celgene's BOD. One and the same.
@tinkering2 @kevinmik @biobull @biolordvr He seems very ACCOMPLISHED!! He has my vote! Bullish
|
|
|
|
Post by sportsrancho on Dec 26, 2017 17:07:40 GMT -5
Just speculation for now .... Celgene Elects Michael A. Friedman, MD to Board of Directors SUMMIT, N.J., Feb 16, 2011 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced the election of Michael A. Friedman, MD, to its Board of Directors. Dr. Friedman is an experienced healthcare leader with a distinguished career in oncology research, regulatory strategy and public healthcare policy. He currently serves as President and Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as director of the organization's Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director's Distinguished Chair. Before leading City of Hope, Dr. Friedman was senior vice president of research and development, medical and public policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America (PhRMA). Additionally, Dr. Friedman previously served as deputy commissioner for the U.S. Food and Drug Administration (FDA), later serving as acting commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens' Oversight Committee, created by California State Proposition 71 to govern the California Institute for Regenerative Medicine and oversee implementation of California's stem cell research effort. "In this time of increased focus on delivering therapeutic value within an evolving healthcare system, someone as experienced in both medical research and public policy continues to strengthen the capability of our Board of Directors," said Robert J. Hugin, Celgene Chief Executive Officer. "Dr. Friedman's guidance will be of tremendous value as we continue to deliver innovative therapies to patients with cancer and other serious diseases around the world." Dr. Friedman has received numerous commendations, including the Surgeon General's Medallion in 1999. He holds a doctorate in medicine from the University of Texas and received his bachelor's degree from Tulane University. He completed postdoctoral training at Stanford University and the National Cancer Institute and is certified in internal medicine and medical oncology. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com. This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control. The Company's actual results, performance, or achievements could be materially different from those projected by these forward-looking statements.The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, 10-Q and 8-K reports.Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements. SOURCE: Celgene Corporation Celgene Corporation Jacqualyn A. Fouse, 908-673-9956 Sr. Vice President and Chief Financial Officer or Tim Smith, 908-673-9951 Director, Investor Relations |
|
|
|
Post by babaoriley on Dec 26, 2017 17:25:17 GMT -5
Well, if it's that Michael Friedman, it would be huge - enough to push the stock up at least .30 in the morning, and close no more than .05 down!  |
|
|
|
Post by cjm18 on Dec 26, 2017 17:28:22 GMT -5
|
|
|
|
Post by babaoriley on Dec 26, 2017 18:45:54 GMT -5
Well, he might not own any now, but they may give him some in connection with the hire. Besides, I might think less of him if he'd bought shares at $5 recently,
|
|
|
|
Post by mnholdem on Dec 26, 2017 19:26:42 GMT -5
Well, if it's that Michael Friedman, it would be huge - enough to push the stock up at least .30 in the morning, and close no more than .05 down! How many times do I have to ask you to use post-split dollars?  |
|
|
|
Post by sportsrancho on Dec 26, 2017 19:44:37 GMT -5
12/26/17, 3:50 PM $mnkd interesting is Stuart Tross, CPO working for both MNKD & Amgen Ventures LLC possible alliance ? www.bloomberg.com/profiles/people/18423614-stuart-a-trossStuart Tross VP/Chief People Officer, Mannkind Corp Career History VP/Chief People Officer Mannkind Corp, 12/2016-PRESENT Sr VP:Human Resources Amgen Ventures LLC, PRESENT Senior VP:Human Resources Amgen Inc, 10/2013-2016 Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts. |
|
|
|
Post by babaoriley on Dec 26, 2017 20:28:41 GMT -5
12/26/17, 3:50 PM $mnkd interesting is Stuart Tross, CPO working for both MNKD & Amgen Ventures LLC possible alliance ? www.bloomberg.com/profiles/people/18423614-stuart-a-trossStuart Tross VP/Chief People Officer, Mannkind Corp Career History VP/Chief People Officer Mannkind Corp, 12/2016-PRESENT Sr VP:Human Resources Amgen Ventures LLC, PRESENT Senior VP:Human Resources Amgen Inc, 10/2013-2016 Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts. Stuart seems fine, Sports, I just hope we don't catch his brother Albert hanging around. |
|
|
|
Post by goyocafe on Dec 26, 2017 21:37:34 GMT -5
12/26/17, 3:50 PM $mnkd interesting is Stuart Tross, CPO working for both MNKD & Amgen Ventures LLC possible alliance ? www.bloomberg.com/profiles/people/18423614-stuart-a-trossStuart Tross VP/Chief People Officer, Mannkind Corp Career History VP/Chief People Officer Mannkind Corp, 12/2016-PRESENT Sr VP:Human Resources Amgen Ventures LLC, PRESENT Senior VP:Human Resources Amgen Inc, 10/2013-2016 Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts. Stuart seems fine, Sports, I just hope we don't catch his brother Albert hanging around. His cousin Alba has a reputation for being rather flighty, too. 🤡 |
|
dj
Newbie
Posts: 2
|
Post by dj on Dec 26, 2017 22:28:27 GMT -5
Just throwing it out there seeing if it sticks. LOL. The Amgen Ventures David A. Piacquad—SVP, Business Development went to Wharton for his MBA. Hmmmm.
|
|
|
|
Post by kc on Dec 26, 2017 22:32:37 GMT -5
I do not want to get too excited. But the doctor Michael Friedman who is on mannkinds‘s board is 73 years of age. I would hope that perhaps there is Another Michael Friedman who might be a younger doctor becoming the CMO for MannKind.
Not to be to Ethnocentric, in the Jewish community with the name Friedman there are lots of doctors. Sort of like Smith might be in other communities.
|
|
|
|
Post by cjm18 on Dec 26, 2017 23:51:49 GMT -5
The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 ...
|
|
|
|
Post by babaoriley on Dec 27, 2017 1:06:45 GMT -5
Stuart seems fine, Sports, I just hope we don't catch his brother Albert hanging around. His cousin Alba has a reputation for being rather flighty, too. 🤡 I was thinking of using Idris Elba, but I'm glad someone caught it! |
|
